Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

5.22-0.09 (-1.71%)

As of 11:39AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	5.31
Open	5.27
Bid	5.20 x 3100
Ask	5.21 x 1300
Day's Range	5.17 - 5.32
52 Week Range	2.50 - 6.79
Volume	690,888
Avg. Volume	3,583,956

Market Cap	1.217B
Beta (5Y Monthly)	1.37
PE Ratio (TTM)	N/A
EPS (TTM)	-1.13
Earnings Date	Oct 27, 2021 - Nov 01, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGEN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Agenus Inc.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.
Rating
Fair Value
Economic Moat
3 days agoMorningstar

All

News

Press Releases

Research Reports

TheStreet.com
Jensen: How to Play Agenus Using Options
Agenus , an oncology drug manufacturer, is a good candidate for a simple covered call strategy, argues Real Money's Bret Jensen. This strategy is cheap for investors since the fees for option orders have declined a lot at the majority of brokerages, according to Jensen. "This strategy provides significant downside protection to most holdings within my portfolio," Jensen wrote recently on Real Money.
GlobeNewswire
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash
Motley Fool
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
Few diseases have wreaked as much havoc as malaria. In 2019, there were an estimated 229 million malaria cases. Last week, the World Health Organization (WHO) recommended widespread use of a malaria vaccine in children.